Objective To construct a risk prediction model for venous thromboembolism(VTE)in patients with acute stroke and analyze its predictive value with decision curve.Methods Clinical data of 265 patients with acute stroke admitted to Department of Neurology of Pingxiang People's Hospital between May 2022 and May 2024 were collected,and 185 of them(69.8％)were assigned to a training set and 80 cases(30.2％)into a validation set.Based on the results of color Doppler ultrasound examination,the patients in the training set were divided into the VTE group(72 cases)and the non-VTE group(113 cases).Multivariate logistic regression analysis was used to identify the risk factors for VTE occurrence in the patients.A prediction model was constructed and a nomegram was developed to visually present the logistic regression prediction model.ROC curve and decision curve analyses were applied to evaluate the predictive performance of the logis-tic regression model.Results The VTE group had significantly larger intracranial hemorrhage volume,higher fibrinogen(FIB),D-dimer and C-reactive protein(CRP)levels,and lower Glasgow Coma Scale(GCS)score than the non-VTE group(P＜0.01).Multivariate logistic regression analysis indicated that intracranial hemorrhage volume(OR=1.243,95％CI:1.015-1.522),FIB(OR=3.161,95％CI:1.711-5.841),CRP(OR=1.595,95％CI:1.283-1.981),and D-dimer(OR=6.234,95％CI:2.693-14.434)were independent risk factors for the occurrence of VTE in the patients with acute stroke,while GCS score(OR=0.587,95％CI:0.413-0.834,P=0.003)was an independent protective factor against the occurrence.A VTE prediction model based on these influencing factors obtained a consistency index of 0.978.The calibration curve results showed that the observed values were in good agreement with the predicted values.ROC curve analysis indicated that the AUC value of the prediction model was 0.978(95％CI:0.945-0.994)in the training set and 0.959(95％CI:0.890-0.991)in the validation set.Decision curve analysis revealed that the model achieved higher net benefit when the threshold probability was between 20％and 80％.Conclusion Intracranial bleeding volume,GCS score,CRP,Didimer and FIB are related influencing factors of VTE in patients with acute stroke,and the prediction model of deci-sion curve based on the above factors is of high prediction efficiency.

A 2-month-old female infant developed fever for 2 days and diarrhea for 1 day. Laboratory tests showed that white blood cell count was 18.8×10 9/L, neutrophil count was 8.3×10 9/L, C-reactive protein was 88.8 mg/L, procalcitonin was 35.9 μg/L, alanine aminotransferase (ALT) was 150 U/L, and aspartate aminotransferase (AST) was 121 U/L. Infectious fever and diarrhea were diagnosed. After 3 days of treatment with ceftriaxone, the diarrhea was improved, but there was still fever. Ceftriaxone was replaced by meropenem (20 mg/kg by intravenous infusion, once per 8 hours). Three days later, the infant′s ALT, AST and white blood cell count returned to normal, but she still experienced recurrent fever (up to 39.0 ℃) and mental fatigue, which was considered to be intracranial infection. The dose of meropenem was doubled (40 mg/kg by intravenous infusion, once per 8 hours), and 3 days later, the infant′s body temperature was normal, but mild yellowish skin occurred, with ALT 1 442 U/L, AST 2 868 U/L, direct bilirubin 20.0 μmol/L, and total bile acid (TBA) 90 μmol/L. Acute liver injury caused by meropenem was considered, the drug was replaced by ceftazidime, and liver-protective treatments such as glutathione and ademetionine were given. After 9 days, the infant′s ALT was 140 U/L, AST was 116 U/L, TBA was 46.3 μmol/L, and yellowish skin disappeared. Two weeks later, her liver function indexes basically returned to normal.

Objective To construct a risk prediction model for venous thromboembolism(VTE)in patients with acute stroke and analyze its predictive value with decision curve.Methods Clinical data of 265 patients with acute stroke admitted to Department of Neurology of Pingxiang People's Hospital between May 2022 and May 2024 were collected,and 185 of them(69.8％)were assigned to a training set and 80 cases(30.2％)into a validation set.Based on the results of color Doppler ultrasound examination,the patients in the training set were divided into the VTE group(72 cases)and the non-VTE group(113 cases).Multivariate logistic regression analysis was used to identify the risk factors for VTE occurrence in the patients.A prediction model was constructed and a nomegram was developed to visually present the logistic regression prediction model.ROC curve and decision curve analyses were applied to evaluate the predictive performance of the logis-tic regression model.Results The VTE group had significantly larger intracranial hemorrhage volume,higher fibrinogen(FIB),D-dimer and C-reactive protein(CRP)levels,and lower Glasgow Coma Scale(GCS)score than the non-VTE group(P＜0.01).Multivariate logistic regression analysis indicated that intracranial hemorrhage volume(OR=1.243,95％CI:1.015-1.522),FIB(OR=3.161,95％CI:1.711-5.841),CRP(OR=1.595,95％CI:1.283-1.981),and D-dimer(OR=6.234,95％CI:2.693-14.434)were independent risk factors for the occurrence of VTE in the patients with acute stroke,while GCS score(OR=0.587,95％CI:0.413-0.834,P=0.003)was an independent protective factor against the occurrence.A VTE prediction model based on these influencing factors obtained a consistency index of 0.978.The calibration curve results showed that the observed values were in good agreement with the predicted values.ROC curve analysis indicated that the AUC value of the prediction model was 0.978(95％CI:0.945-0.994)in the training set and 0.959(95％CI:0.890-0.991)in the validation set.Decision curve analysis revealed that the model achieved higher net benefit when the threshold probability was between 20％and 80％.Conclusion Intracranial bleeding volume,GCS score,CRP,Didimer and FIB are related influencing factors of VTE in patients with acute stroke,and the prediction model of deci-sion curve based on the above factors is of high prediction efficiency.

A 2-month-old female infant developed fever for 2 days and diarrhea for 1 day. Laboratory tests showed that white blood cell count was 18.8×10 9/L, neutrophil count was 8.3×10 9/L, C-reactive protein was 88.8 mg/L, procalcitonin was 35.9 μg/L, alanine aminotransferase (ALT) was 150 U/L, and aspartate aminotransferase (AST) was 121 U/L. Infectious fever and diarrhea were diagnosed. After 3 days of treatment with ceftriaxone, the diarrhea was improved, but there was still fever. Ceftriaxone was replaced by meropenem (20 mg/kg by intravenous infusion, once per 8 hours). Three days later, the infant′s ALT, AST and white blood cell count returned to normal, but she still experienced recurrent fever (up to 39.0 ℃) and mental fatigue, which was considered to be intracranial infection. The dose of meropenem was doubled (40 mg/kg by intravenous infusion, once per 8 hours), and 3 days later, the infant′s body temperature was normal, but mild yellowish skin occurred, with ALT 1 442 U/L, AST 2 868 U/L, direct bilirubin 20.0 μmol/L, and total bile acid (TBA) 90 μmol/L. Acute liver injury caused by meropenem was considered, the drug was replaced by ceftazidime, and liver-protective treatments such as glutathione and ademetionine were given. After 9 days, the infant′s ALT was 140 U/L, AST was 116 U/L, TBA was 46.3 μmol/L, and yellowish skin disappeared. Two weeks later, her liver function indexes basically returned to normal.

An 11-year-old boy received tofacitinib (oral 7.5 mg once daily) on the basis of methotrexate therapy (oral 10 mg once a week) due to poor control of juvenile idiopathic arthritis, and the symptoms were relieved. The boy′s liver function was normal before using tofacitinib. After more than 2 months of combined use of the 2 drugs, laboratory tests showed alanine aminotransferase (ALT) 178 U/L and aspartate aminotransferase (AST) 78 U/L. No intervention was given because there were no clinical symptoms. His liver enzyme elevated significantly (ALT 586 U/L, AST 170 U/L) after continued medication for 1 month. After excluding viral hepatitis, autoimmune hepatitis, and other liver diseases, drug-induced liver injury was considered. Methotrexate was discontinued, tocilizumab was added, and liver protection therapy with reduced glutathione and magnesium isoglycyrrhizinate was given. Eleven days of methotrexate withdrawal, the laboratory tests showed ALT 512 U/L and AST 194 U/L. Then tofacitinib was discontinued and hepatic enzyme decreased significantly (ALT 150 U/L, AST 41 U/L) 3 days later. The liver injury was considered to be related to tofacitinib. The liver protection therapy was continued for 1 week, and the liver function examination showed ALT 41 U/L and AST 35 U/L.

An 11-year-old boy received tofacitinib (oral 7.5 mg once daily) on the basis of methotrexate therapy (oral 10 mg once a week) due to poor control of juvenile idiopathic arthritis, and the symptoms were relieved. The boy′s liver function was normal before using tofacitinib. After more than 2 months of combined use of the 2 drugs, laboratory tests showed alanine aminotransferase (ALT) 178 U/L and aspartate aminotransferase (AST) 78 U/L. No intervention was given because there were no clinical symptoms. His liver enzyme elevated significantly (ALT 586 U/L, AST 170 U/L) after continued medication for 1 month. After excluding viral hepatitis, autoimmune hepatitis, and other liver diseases, drug-induced liver injury was considered. Methotrexate was discontinued, tocilizumab was added, and liver protection therapy with reduced glutathione and magnesium isoglycyrrhizinate was given. Eleven days of methotrexate withdrawal, the laboratory tests showed ALT 512 U/L and AST 194 U/L. Then tofacitinib was discontinued and hepatic enzyme decreased significantly (ALT 150 U/L, AST 41 U/L) 3 days later. The liver injury was considered to be related to tofacitinib. The liver protection therapy was continued for 1 week, and the liver function examination showed ALT 41 U/L and AST 35 U/L.

Objective:To determine the related substances in benzalkonium chloride used as a pharmaceutical adjuvant, and com-pare the quality at home and abroad. Methods:An HPLC method was used with an ODS-HYPERSIL C18 column(250 mm × 4. 6 mm, 5 μm). The detection wavelength was 210 nm and 257 nm. The flow rate was 1. 0 ml· min-1 and the column temperature was 30℃. The injection volume was 20 ml. The mobile phase was A ( dissolving 1. 09 g sodium1-hexanesulfonate and 6. 9 g sodium dihydrogen phosphate in water, adjusting pH to 3. 5 with phosphoric acid and diluting to 1 000. 0 ml) and B ( methanol) with gradient elution. Results:The content of benzaldehyde in the samples at home and abroad was low. The content of benzyl alcohol in the samples from a-broad was qualified, which was significantly higher than that in the domestic samples. The content of benzyl chloride in the domestic samples was higher than that in the samples from abroad. Conclusion:The method is simple and fast, which is suitable for comparing the related substances of domastic and imported samples. At the same time, the study provides basis for enterprises to choose benzalko-nium chloride rationally.

Objective:To compare the quality differences in benzalkonium chloride samples from domestic and abroad to provide references for the quality standard revision for benzalkonium chloride in Chinese pharmacopoeia. Methods: The ratio of alkyl compo-nents was determined according to the method described in USP 38, and the total content of benzalkonium chloride was determined ac-cording to the method recorded in Chinese Pharmacopoeia (2015 edition) and USP 38, respectively. Results:According to the results of composition ratio of alkyl, the fraction defective of domestic samples and imported samples was 100% and 50%, respectively. The content difference between the values calculated by the methods in the two pharmacopoeias showed that the total content of domestic samples changed from 3. 86% to 4. 15%, and that of imported samples changed from 1. 15% to 3. 90%. Conclusion:There are sig-nificant differences in the quality of benzalkonium chloride between domestic samples and imported samples. It is recommended that the ratio of alkyl components should be supplemented in our pharmacopoeia referring to the method in USP 38 and the total content calcula-tion formula for benzalkonium chloride should be revised to improve the quality standard for benzalkonium chloride.